Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted:
“Day 3 of GU24 ASCO Highlights
1. KN564: Adj Pembro w/ +ve OS
2. LITESPARK005
3. Updates in RCC:
– CM214
– CM9ER
– CLEAR
– SubC Nivo
1. KN564: Pembro was approved for high risk adj RCC in November 2021 based off this study. Today, we saw an update at 57mos with OS benefit.
– Median not reached (55 vs 86 OS events), HR: 0.62
– Pembro will/should remain the SoC in this setting.
2. LITESPARK005: Belzutifan was approved in December 2023 after PDL1/TKI based off study. At the time: Improved PFS HR: 0.75. Now, patient reported outcomes:
– QoL on both scales (FKSI and QLQ) was better with belzutifan
– Awaiting OS (was immature at the time of approval).
3. Updates for RCC:
– CM214: Ipi/Nivo combo continues to show OS benefit in intermediate and poor risk. OS has improved in favorable category over period of time.
– CM9ER: Nivo/Cabo ongoing OS benefit (46.5 most and HR: 0.77)
– CLEAR: Pembro/Len benefit in all tumor burden/sizes
– SubC Nivo ≤ 5 mins and was non-inferior to Nivo IV.”
Source: Oncology Brothers/X